Inventor · disambiguated record
Benjamin Jones
Also filed as: JONES BENJAMIN · JONES BENJAMIN D
25 granted patents·14 pending applications·145 citations·filing 2003–2023
95Inventor score
Files withTAKEDA PHARMACEUTICAL8BAYER PHARMACEUTICALS CORP5ERASCA INC5TAKEDA PHARMACEUTICALS CO5BAYER HEALTHCARE LLC3
Top patents by PatentIndex Score
39 records- 0193US7928105B2Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-onesTAKEDA PHARMACEUTICAL·Filed 2010·Granted Apr 19, 2011·24 cites·21 claims
- 0292US8440689B2Fused heteroaromatic pyrrolidinonesARIKAWA YASUYOSHI·Filed 2010·Granted May 14, 2013·23 cites·28 claims
- 0391US8138168B1Renin inhibitorsJONES BENJAMIN·Filed 2008·Granted Mar 20, 2012·23 cites·90 claims
- 0488US7563791B2Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER PHARMACEUTICALS CORP·Filed 2005·Granted Jul 21, 2009·14 cites·8 claims
- 0586US9040522B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2014·Granted May 26, 2015·7 cites·10 claims
- 0683US8318727B2Polo-like kinase inhibitorsCAO SHELDON X·Filed 2010·Granted Nov 27, 2012·13 cites·13 claims
- 0783US2023295171A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 0882US9345713B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICAL·Filed 2015·Granted May 24, 2016·3 cites·10 claims
- 0981US12162893B2Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2021·Granted Dec 10, 2024·1 cites·4 claims
- 1080US8124606B2Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-onesGANGLOFF ANTHONY R·Filed 2011·Granted Feb 28, 2012·4 cites·17 claims
- 1180US7928227B22-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disordersBAYER HEALTHCARE LLC·Filed 2004·Granted Apr 19, 2011·10 cites·28 claims
- 1280US7585888B2Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2008·Granted Sep 8, 2009·4 cites·5 claims
- 1379US9708296B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jul 18, 2017·2 cites·8 claims
- 1479US7384947B2Fused tricyclic heterocycles useful for treating hyper-proliferative disordersBAYER HEALTHCARE LLC·Filed 2006·Granted Jun 10, 2008·2 cites·5 claims
- 1578US9108970B2Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICAL·Filed 2013·Granted Aug 18, 2015·2 cites·31 claims
- 1677US8450323B2Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazineGANGLOFF ANTHONY R·Filed 2012·Granted May 28, 2013·3 cites·16 claims
- 1775US9181255B2Fused heteroaromatic pyrrolidinones as SYK inhibitorsARIKAWA YASUYOSHI·Filed 2010·Granted Nov 10, 2015·2 cites·28 claims
- 1872US8822470B2Substituted pyrido[2,3-b]pyrazinesTAKEDA PHARMACEUTICAL·Filed 2013·Granted Sep 2, 2014·1 cites·17 claims
- 1970US11845761B2Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2022·Granted Dec 19, 2023·0 cites·30 claims
- 2070US7144885B2Fused tricyclic heterocycles useful for treating hyper-proliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Dec 5, 2006·4 cites·26 claims
- 2168US2022306634A1Fused heteroaromatic pyrrolidinonesCALITHERA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2267US7351735B2Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Apr 1, 2008·3 cites·21 claims
- 2363US2018141951A1Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICALS CO·Filed 2017·Application pending·0 cites
- 2462US9944626B26-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Apr 17, 2018·0 cites·7 claims
- 2562US9187497B2Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)GANGLOFF ANTHONY R·Filed 2014·Granted Nov 17, 2015·0 cites·21 claims
- 2662US8338595B2Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisDIXON JULIE A·Filed 2009·Granted Dec 25, 2012·0 cites·8 claims
- 2760US10407409B26-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHDTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Sep 10, 2019·0 cites·2 claims
- 2860US2023107642A1Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2021·Application pending·0 cites
- 2957US2015336964A1Fused heteroaromatic pyrrolidinonesTAKEDA PHARMACEUTICAL·Filed 2015·Application pending·0 cites
- 3055US2024383921A1Amide and urea-containing tricyclic kras inhibitorsERASCA INC·Filed 2022·Application pending·0 cites
- 3154US2023203063A1Tricyclic pyridones and pyrimidonesERASCA INC·Filed 2022·Application pending·0 cites
- 3253US2013225809A1Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER HEALTHCARE LLC·Filed 2012·Application pending·0 cites
- 3352US2023150981A1N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonistsTAKEDA PHARMACEUTICAL COMPNAY LTD·Filed 2021·Application pending·0 cites
- 3450US2009291938A1Polo-like kinase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2008·Application pending·0 cites
- 3548US2009105251A1Renin inhibitorsJONES BENJAMIN·Filed 2007·Application pending·0 cites
- 3646US2010210635A1Renin inhibitorsTAKEDA PHARMACEUTICAL·Filed 2007·Application pending·0 cites
- 3743US11426397B2Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Aug 30, 2022·0 cites·17 claims
- 3842US2008293696A12-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic AgentsBAYER PHARMACEUTICALS CORP·Filed 2005·Application pending·0 cites
- 3938US2020277262A1N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivativesJONES BENJAMIN·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benjamin Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →